PYC Therapeutics amps up dosage in blindness trial
Emerging from trading halt, PYC Therapeutics (ASXYC) shares this morning retreated 7.5% after the company updated investors on its dosing study of its lead drug candidate for the rare childhood blinding disorder retinitis pigmentosa type 11 (RP11).
We thought it was good news, but the market moves in mysterious ways.
The gist is that with a good safety and tolerability profile established in a single-dose study, the trend continued with patients receiving three treatments at the highest dose.
What’s more, the vision improvement seen in the single-dose study has been sustained.
VP-001 is the first drug candidate to have progressed into human trials for RP11. As we reported yesterday, it has been conferred ‘orphan’ drug status by the US Food & Drug Administration.
The company intends to provide a further update on its two multiple dosing studies in the first half of 2025.
PYC shares were trading at 18.5 cents.
PYC Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
YC) shares this morning retreated 7.5% after the company updated investors on its dosing study of its lead drug candidate for the rare childhood blinding disorder retinitis pigmentosa type 11 (RP11).
(20min delay)